Stocks moved in after-hours trade as corporate reports and program selections filtered through the market. Technology, software, biotech, leisure and aviation-related names all recorded meaningful reactions tied to fresh data and updates.
Hewlett Packard Enterprise (HPE) was among the winners, rising 2% after releasing a quarterly report and offering guidance investors found encouraging. The company reported revenue of $9.3 billion for the period, an increase of 18% compared with the same quarter a year earlier.
In software and local-search technology, Yext, Inc. (YEXT) slipped 4% after narrowly missing expectations on both the top and bottom lines. Yext's fourth-quarter earnings per share came in at $0.14, which is $0.01 below the analysts' consensus of $0.15. Quarterly revenue was $112 million versus a consensus estimate of $113.92 million.
Vertex Pharmaceuticals (VRTX) gained 7% following interim data from the phase 3 RAINIER study of povetacicept in IgA nephropathy. The company said the trial met its primary objective, and the positive interim results were cited as the catalyst for the stock move.
Vail Resorts (MTN) fell 2.25% after reporting second-quarter results that came up short of analyst estimates. The ski and resort operator posted Q2 earnings per share of $5.87, missing the consensus view by $0.38, which stood at $6.25. Revenue for the quarter was $1.08 billion, below the consensus estimate of $1.12 billion.
Joby Aviation Inc. (JOBY) rose 3% after announcing it had been selected as a partner in multiple applications under the White House-backed Electric Vertical Takeoff and Landing Integration Pilot Program. The company highlighted its inclusion in those applications as the driver of the after-hours uptick.
Also noted in market commentary was investor interest in whether Vertex remains an attractive buy given the recent trial update. The article referenced an AI-driven strategy tool that evaluates companies using a wide range of financial metrics and that has previously identified stocks with significant gains, and it suggested investors could consult such a tool to see how Vertex compares to other ideas.
Overall, the after-hours session reflected a mix of earnings-driven weakness and event-driven strength across several sectors, with market reactions closely tied to whether results met or missed consensus estimates or provided clear clinical or program-related catalysts.